2021 regulatory trends in China, including antitrust, data privacy, sanctions, healthcare, PE/VC, capital markets, IP, banking & finance, TMT and arbitration.
China joins the WIPO treaty on protecting industrial designs; Hong Kong, mainland M&A hits record heights in 2021 despite regulatory headwinds; and e-CNY to be piloted in retail shops across Hong Kong
Fay Zhou and Arthur Peng of Linklaters review major developments in China's anti-trust regulations that aim to offer clearer guidance and more efficient enforcement actions that can impact on this area of law for the next decade. These developments include stronger deterrence, expanded substantive prohibitions, public interest litigation and a firmer stance against consolidation.
With the entrenchment of reciprocal US-China sanctions and export controls in the past year, counsel have helped clients enact fundamental changes to their approach to making deals, from contractual terms to due diligence
The U.S. adds 12 Chinese entities to its export blacklist; Rules regulating listed companies to be consolidated; Didi ordered by regulators to delist from NYSE
Hong Kong finalizes secondary listing reforms to attract more Greater China Issuers; SAMR fines tech giants for failing to declare transactions; and German insurer Allianz approved to take full control of life insurance business
Hong Kong Court grants landmark interlocutory injunctions in IP Case; Draft amendment to Anti-Monopoly Law targets platform economy; 4 G-SIBs to comply with new TLAC requirements By 2025
The HKEX has published a consultation paper to introduce its SPAC listing regime; US-China bilateral tech investment plummets 96%; and MIIT calls on telecoms and auto companies to strengthen data protection policies.
